CAR T Referral Process: Insights From Kansas : Episode 4

University of Kansas Medical Center Insights: CAR T Referral Process

January 20, 2025

By Al-Ola Abdallah, MD
Muhammad Umair Mushtaq, MD

Opinion

Video

Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

Now Viewing

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

Walk us through the typical chimeric antigen receptor T-cell referral process at your institution, from the initial community physician outreach to the patient evaluation and selection.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!